Nobivac Feline 2-FeLV (Canada)

FELINE LEUKEMIA VACCINE

Killed Virus

FOR ANIMAL USE ONLY

IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.

THIMEROSAL FREE

Nobivac Feline 2-FeLV Indications

This product has been shown to be effective for vaccination of healthy cats 9 weeks of age or older against feline leukemia viruses. Duration of Immunity is at least 2 years. To review efficacy and safety data, go to productdata.aphis.usda.gov.

This product has been shown to be effective against persistent viremia in cats exposed to virulent feline leukemia virus.

Dosage and Administration

Prior to use, warm the Nobivac^® Feline 2-FeLV to room temperature and shake well. Two doses are required for primary immunization. A 22 gauge needle is recommended for the vaccination of FeLV.

Initial vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly at 9 weeks of age or older.

Second vaccination: Inject 1 dose (1 mL) subcutaneously or intramuscularly 3 to 4 weeks following the initial vaccination.

Contact your veterinarian or manufacturer for more information on revaccination frequency.

Precautions

● Store at 2° - 8°C (35°-46°F).

● Do not freeze.

● Use new, non-chemically sterilized needles and syringes.

● Do not mix with other products.

● In case of human exposure, contact a physician.

Warnings

● Contains gentamicin and amphotericin B as preservatives.

● Some reports suggest that in cats, the administration of certain veterinary biologicals may induce the development of injection-site fibrosarcomas.

● Do not vaccinate pregnant cats.

● The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.

● It is important to realize that certain conditions and events may cause some cats to be unable to develop or maintain an adequate immune response following vaccination. Prior exposure to the disease, or disease latency, are conditions in which vaccination will not alter the course of the disease. Therefore, diagnostic testing of all cats for FeLV antigen prior to vaccination is recommended. Also, vaccination with this product will not offer cross-protection against feline immunodeficiency virus (FIV), another feline retrovirus. It is important to advise the cat owner of these situations prior to vaccination.

Intervet Inc. d/b/a Merck Animal Health

Omaha, NE 68103 USA

VLN 165A/PCN 1555.20

1 800 224-5318 (USA)

1 866 683-7838 (Canada)

For patent information:

http://www.merck.com/product/patent/home.html

CPN: 1208273.1